 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- lenvatinib gel suspension (AIV007) / AiViva BioPharma
Systemic and Ocular Pharmacokinetic Profile Following Periocular Administration of AIV007 Gel Formulation (DEMAND) - Sep 24, 2024 - Abstract #AAO2024AAO_2430;
Conclusion Following a single periocular injection, AIV007 in ocular tissues remained at therapeutically relevant levels over 6 months, with low systemic exposure. AIV007 gel demonstrated a slow and prolonged drug release.
- || lenvatinib gel suspension (AIV007) / AiViva BioPharma
Enrollment open: Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME (clinicaltrials.gov) - Mar 30, 2023
P1, N=30, Recruiting, Sponsor: AiViva BioPharma, Inc.
AIV007 gel demonstrated a slow and prolonged drug release. Not yet recruiting --> Recruiting
- || lenvatinib gel suspension (AIV007) / AiViva BioPharma
New P1 trial: Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME (clinicaltrials.gov) - Jan 26, 2023
P1, N=30, Not yet recruiting, Sponsor: AiViva BioPharma, Inc.
- || lenvatinib gel suspension (AIV007) / AiViva BioPharma
Trial completion, Enrollment change, Trial completion date: Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - May 13, 2022
P1, N=3, Completed, Sponsor: AiViva BioPharma, Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=24 --> 3 | Trial completion date: Sep 2021 --> Feb 2022
- || lenvatinib gel suspension (AIV007) / AiViva BioPharma
Enrollment open: Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jan 12, 2021
P1, N=24, Recruiting, Sponsor: AiViva BioPharma, Inc.
Recruiting --> Completed | N=24 --> 3 | Trial completion date: Sep 2021 --> Feb 2022 Not yet recruiting --> Recruiting
- | lenvatinib gel suspension (AIV007) / AiViva BioPharma
New P1 trial: Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jun 8, 2020
P1, N=24, Not yet recruiting, Sponsor: AiViva BioPharma, Inc.